Europe to decide on Novavax's COVID ワクチン in October
Sept 21 (Reuters) - The European 薬／医学s 機関 (EMA) 推定する／予想するs to decide on the use of Novavax's updated COVID-19 ワクチン in October, its director Emer Cooke said on Thursday.
The 機関 had started the evaluation 過程 for the protein-based 発射 on Aug. 24, Cooke said at a 圧力（をかける） 会議／協議会.
EU regulators recently gave the green light for an updated COVID-19 ワクチン from Pfizer and its German partner BioNTech, which 的s the XBB.1.5 variant of Omicron.
Moderna's updated 発射 is also on 跡をつける to 勝利，勝つ 是認.
The EMA's human 薬／医学s 委員会 (CHMP) will discuss the 発射 at its 会合 in October, に引き続いて which the 機関 "should have an 結果", Cooke said.
The CHMP is scheduled to 会合，会う from Oct. 9 to 12, によれば the 機関's website.
Novavax said on Thursday it 推定する／予想するs to be 含むd in the 会合 and 計画（する）s to have the first doses 配達するd to European countries as 早期に as October, under 存在するing 前進するd 購入（する） 協定s. The ワクチン is also under review by the U.S. Food and 麻薬 行政.
Novavax said it was working closely with the FDA as the health regulator 完全にするs the review.
Updated mRNA-based 発射s from 競争相手s Pfizer/BioNTech and Moderna have also been 権限を与えるd for use in the 部隊d 明言する／公表するs.
Novavax's 株 were 負かす／撃墜する about 2% at $6.89. (報告（する）／憶測ing by Bhanvi Satija in Bengaluru and Michael Erman in New York; Editing by Saumyadeb Chakrabarty and Sriraj Kalluvila)
